The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia - PubMed (original) (raw)
Review
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
R A DeFronzo et al. Diabetes Obes Metab. 2012 Jan.
Abstract
The maintenance of normal glucose homeostasis requires a complex, highly integrated interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system. Recent studies have showed that the kidneys also play a central role in glucose homeostasis by reabsorbing all the filtered glucose, an adaptive mechanism that ensures sufficient energy is available during fasting periods. This mechanism becomes maladaptive in diabetes, however, as hyperglycaemia augments the expression and activity of the sodium-glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney. As a result, glucose reabsorption may be increased by as much as 20% in individuals with poorly controlled diabetes. SGLT2 is a low-affinity, high-capacity glucose transport protein that reabsorbs 90% of filtered glucose, while the high-affinity, low-capacity SGLT1 transporter reabsorbs the remaining 10%. SGLT2 represents a novel target for the treatment of diabetes. In animal studies, SGLT2 inhibition reduces plasma glucose levels, resulting in improved β-cell function and enhanced insulin sensitivity in liver and muscle. Human studies have confirmed the efficacy of SLGT2 inhibitors in improving glucose control and reducing the A1c. Because the mechanism of SGLT2 inhibition is independent of circulating insulin levels or insulin sensitivity, these agents can be combined with all other antidiabetic classes, including exogenous insulin. Although the long-term efficacy and safety of SGLT2 inhibitors remain under study, the class represents a novel therapeutic approach with potential for the treatment of both type 2 and 1 diabetes.
© 2011 Blackwell Publishing Ltd.
Similar articles
- Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ. Bailey CJ. Trends Pharmacol Sci. 2011 Feb;32(2):63-71. doi: 10.1016/j.tips.2010.11.011. Epub 2011 Jan 4. Trends Pharmacol Sci. 2011. PMID: 21211857 Review. - SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA. Jabbour SA. Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731. Postgrad Med. 2014. PMID: 24393758 Review. - Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P. Raskin P. Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Diabetes Metab Res Rev. 2013. PMID: 23463735 Review. - SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. Ghosh RK, et al. J Clin Pharmacol. 2012 Apr;52(4):457-63. doi: 10.1177/0091270011400604. Epub 2011 May 4. J Clin Pharmacol. 2012. PMID: 21543663 Review. - Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA, Wright EM, Vallon V. Gallo LA, et al. Diab Vasc Dis Res. 2015 Mar;12(2):78-89. doi: 10.1177/1479164114561992. Epub 2015 Jan 23. Diab Vasc Dis Res. 2015. PMID: 25616707 Free PMC article. Review.
Cited by
- Residual Kidney Function in Hemodialysis: Its Importance and Contribution to Improved Patient Outcomes.
Obi Y, Raimann JG, Kalantar-Zadeh K, Murea M. Obi Y, et al. Toxins (Basel). 2024 Jun 28;16(7):298. doi: 10.3390/toxins16070298. Toxins (Basel). 2024. PMID: 39057938 Free PMC article. Review. - Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers.
Chen Q, Yu C, Wu Q, Song R, Liu Y, Feng S, Yu C, Jia J. Chen Q, et al. Drug Des Devel Ther. 2024 May 29;18:1855-1864. doi: 10.2147/DDDT.S433377. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38828023 Free PMC article. - Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes.
Stachteas P, Patoulias D, Popovic DS, Athanasiadou P, Fragakis N. Stachteas P, et al. touchREV Endocrinol. 2024 Apr;20(1):19-24. doi: 10.17925/EE.2024.20.1.6. Epub 2023 Dec 19. touchREV Endocrinol. 2024. PMID: 38812664 Free PMC article. Review. - Ketoacidosis and SGLT2 Inhibitors: A Narrative Review.
Morace C, Lorello G, Bellone F, Quartarone C, Ruggeri D, Giandalia A, Mandraffino G, Minutoli L, Squadrito G, Russo GT, Marini HR. Morace C, et al. Metabolites. 2024 May 6;14(5):264. doi: 10.3390/metabo14050264. Metabolites. 2024. PMID: 38786741 Free PMC article. Review. - A paper-based dual functional biosensor for safe and user-friendly point-of-care urine analysis.
Li Y, Kong Y, Hu Y, Li Y, Asrosa R, Zhang W, Deka Boruah B, Yetisen AK, Davenport A, Lee TC, Li B. Li Y, et al. Lab Chip. 2024 Apr 30;24(9):2454-2467. doi: 10.1039/d4lc00163j. Lab Chip. 2024. PMID: 38644805 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials